Palumbo, Joseph M.
Thomas, Brian F.
Budimirovic, Dejan
Siegel, Steven
Tassone, Flora
Hagerman, Randi
Faulk, Christopher
O’Quinn, Stephen
Sebree, Terri
Funding for this research was provided by:
Zynerba Pharmaceuticals Inc.
Article History
Received: 15 March 2022
Accepted: 28 December 2022
First Online: 9 January 2023
Declarations
:
: Not applicable.
: Not applicable.
: JMP was an employee of Zynerba Pharmaceuticals at the time of the manuscript development. BFT was a consultant to Zynerba Pharmaceuticals at the time of the manuscript development. DB was an investigator for the CONNECT-FX study for Zynerba Pharmaceuticals. SS is on the Scientific Advisory Board for fragile X syndrome for Zynerba Pharmaceuticals. FT and CF have no competing interests. RH has received funding from Zynerba Pharmaceuticals for the conduct of the study as an investigator and is on scientific advisory board for fragile X syndrome for Zynerba Pharmaceuticals. SO’Q and TS are employees of Zynerba Pharmaceuticals.